Dihexa half-life & pharmacokinetics

Reported half-life

Limited published pharmacokinetic data. Reported oral bioavailability in rodents is meaningful (~10-20%) despite the peptide structure — attributed to the N-terminal hexanoyl modification and the small molecular size. Plasma half-life is short (hours) but the functional pharmacological effect on dendritic-spine formation outlasts plasma exposure substantially through the persistent structural changes induced.

The half-life and pharmacokinetic profile of Dihexa reported above is drawn from the published pre-clinical literature. Plasma half-life describes the time taken for the circulating concentration to fall by half after a single dose; tissue half-life — which may be longer for peptides retained in specific organs or matrices — is a distinct and often more relevant parameter for healing research, where the duration of exposure at the injury site matters more than the systemic exposure profile.

Routes of administration studied

• Oral (research; principal route given oral bioavailability)
• Subcutaneous injection (research)
• Intraperitoneal injection (rodent research models)

Different routes produce materially different pharmacokinetic profiles for the same peptide. Subcutaneous administration generally produces flatter, more sustained plasma profiles than intravenous bolus dosing; intraperitoneal administration (common in rodent models) is not directly translatable to human routes; oral administration faces the additional challenge of luminal and brush-border peptidase degradation, which is why most research peptides have very low oral bioavailability without protective formulation.

Drug class

Synthetic hexapeptide angiotensin IV analogue; HGF/c-Met receptor signalling potentiator; orally-bioavailable cognitive research compound.

Mechanism context

Half-life interpretation depends on the underlying mechanism. Dihexa acts as follows:

Dihexa (PNB-0408, N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide) is a synthetic hexapeptide developed by Joseph Harding's research group at Washington State University as a cognitive enhancer derived from angiotensin IV through systematic structure-activity optimisation. The molecular design started from angiotensin IV (Val-Tyr-Ile-His-Pro-Phe), the hexapeptide product of further hydrolysis of angiotensin II that was characterised in the 1990s as a regulator of central nervous system functions including learning and memory, with the goal of producing a stable, orally-bioavailable analogue retaining the cognitive-enhancing activity while addressing the rapid peptidase degradation of native angiotensin IV. The result was a markedly modified analogue retaining only the core Tyr-Ile recognition element of native angiotensin IV with N-terminal hexanoyl-modification for protease resistance and C-terminal aminohexanoic acid extension for receptor binding optimisation.

See the full Dihexa research profile for the complete mechanism summary, history, study citations, and references.

Practical considerations

Short plasma half-life does not necessarily mean short duration of biological effect. Many peptides — including BPC-157, GHK-Cu, and the thymosin-derived compounds — exhibit tissue retention or mechanistic effects (gene expression, signalling cascades) that outlast plasma exposure by hours to days. The pharmacological half-life and the biological-effect half-life are distinct parameters that must both be specified in any rigorous research design. Repeated-dose protocols should account for accumulation only where tissue half-life is genuinely long; for most peptides with short plasma half-life and rapid degradation, accumulation is not a practical concern.

For dose ranges in published research, see the dosing reference page. For reconstitution guidance, see the reconstitution reference page.